WO2013054199A3 - Cmv antigens and uses thereof - Google Patents
Cmv antigens and uses thereof Download PDFInfo
- Publication number
- WO2013054199A3 WO2013054199A3 PCT/IB2012/002491 IB2012002491W WO2013054199A3 WO 2013054199 A3 WO2013054199 A3 WO 2013054199A3 IB 2012002491 W IB2012002491 W IB 2012002491W WO 2013054199 A3 WO2013054199 A3 WO 2013054199A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cmv antigens
- cmv
- antigens
- methods
- relates
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Abstract
The present invention relates to immunogenic compositions comprising CMV antigens and methods for preparing compositions that contain CMV antigens. The invention also relates to methods for inducing an immune response to CMV.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/350,988 US20140348863A1 (en) | 2011-10-12 | 2012-10-11 | Cmv antigens and uses thereof |
EP12816105.6A EP2766385A2 (en) | 2011-10-12 | 2012-10-11 | Cmv antigens and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161546150P | 2011-10-12 | 2011-10-12 | |
US61/546,150 | 2011-10-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013054199A2 WO2013054199A2 (en) | 2013-04-18 |
WO2013054199A3 true WO2013054199A3 (en) | 2013-08-01 |
Family
ID=47561668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2012/002491 WO2013054199A2 (en) | 2011-10-12 | 2012-10-11 | Cmv antigens and uses thereof |
Country Status (3)
Country | Link |
---|---|
US (1) | US20140348863A1 (en) |
EP (1) | EP2766385A2 (en) |
WO (1) | WO2013054199A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8883814B2 (en) | 2006-06-05 | 2014-11-11 | Keyview Labs, Inc. | Compositions and methods for enhancing brain function |
PL2590626T3 (en) | 2010-07-06 | 2016-04-29 | Glaxosmithkline Biologicals Sa | Liposomes with lipids having an advantageous pka-value for rna delivery |
ES2770335T3 (en) | 2010-07-06 | 2020-07-01 | Glaxosmithkline Biologicals Sa | RNA administration to trigger multiple immune pathways |
WO2012006369A2 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Immunisation of large mammals with low doses of rna |
LT3981427T (en) | 2010-08-31 | 2022-08-10 | Glaxosmithkline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding rna |
MX363307B (en) | 2010-10-11 | 2019-03-20 | Novartis Ag Star | Antigen delivery platforms. |
CA2840989A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
CN109045294A (en) * | 2013-01-10 | 2018-12-21 | 思齐乐 | Influenza virus immunization Immunogenic Compositions and its application |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2015073788A2 (en) * | 2013-11-15 | 2015-05-21 | President And Fellows Of Harvard College | Methods and compositions for the treatment of hcmv |
AU2014359276B2 (en) * | 2013-12-03 | 2021-01-28 | Hookipa Biotech Gmbh | CMV vaccines |
EP3047856A1 (en) * | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv antigens and uses thereof |
US20180030417A1 (en) * | 2015-02-16 | 2018-02-01 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method of altering expression of alternative viral glycoprotein complexes |
EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | Human cytomegalovirus vaccine |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
JP6980780B2 (en) | 2016-10-21 | 2021-12-15 | モデルナティーエックス, インコーポレイテッド | Human cytomegalovirus vaccine |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
TWI810589B (en) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | Human cytomegalovirus gb polypeptide |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
EP4108298A1 (en) * | 2021-06-23 | 2022-12-28 | Albert-Ludwigs-Universität Freiburg | Application of hcmv gp34- and gp68-specific antibodies and fragments thereof for prevention, therapy and diagnostics of hcmv disease |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004055166A2 (en) * | 2002-12-13 | 2004-07-01 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
WO2005007689A1 (en) * | 2003-07-11 | 2005-01-27 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
WO2007146024A2 (en) * | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
WO2012006359A1 (en) * | 2010-07-06 | 2012-01-12 | Novartis Ag | Delivery of self-replicating rna using biodegradable polymer particles |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4186745A (en) | 1976-07-30 | 1980-02-05 | Kauzlarich James J | Porous catheters |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
JPH0731857B2 (en) | 1988-02-19 | 1995-04-10 | 三洋電機株式会社 | Reel base drive device in magnetic recording / reproducing apparatus |
WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
DK0452457T3 (en) | 1989-11-03 | 1998-03-02 | Univ Vanderbilt | Method for in vivo removal of functional foreign genes |
US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
AU4528493A (en) | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5397307A (en) | 1993-12-07 | 1995-03-14 | Schneider (Usa) Inc. | Drug delivery PTCA catheter and method for drug delivery |
JP3403233B2 (en) | 1994-01-20 | 2003-05-06 | テルモ株式会社 | Balloon catheter |
FR2726003B1 (en) | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | CULTURE MEDIUM OF AVIAN TOTIPOTENT EMBRYONIC CELLS, METHOD FOR CULTURING THESE CELLS, AND AVIAN TOTIPOTENT EMBRYONIC CELLS |
WO1996015811A1 (en) | 1994-11-17 | 1996-05-30 | Imperial College Of Science, Technology & Medicine | Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand |
US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
US5721354A (en) * | 1995-03-31 | 1998-02-24 | Aviron | Human cytomegalovirus DNA sequences |
DE19612967A1 (en) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Process for the propagation of influenza viruses in cell culture, and the influenza viruses obtainable by the process |
US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
US6090619A (en) | 1997-09-08 | 2000-07-18 | University Of Florida | Materials and methods for intracellular delivery of biologically active molecules |
US6129705A (en) | 1997-10-01 | 2000-10-10 | Medtronic Ave, Inc. | Drug delivery and gene therapy delivery system |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
EP1103610A1 (en) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
US7204990B1 (en) * | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
AU2002247733B2 (en) * | 2001-02-21 | 2007-12-13 | The Wistar Institute Of Anatomy And Biology | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
FR2832423B1 (en) | 2001-11-22 | 2004-10-08 | Vivalis | EXOGENOUS PROTEIN EXPRESSION SYSTEM IN AN AVIAN SYSTEM |
FR2836924B1 (en) | 2002-03-08 | 2005-01-14 | Vivalis | AVIAN CELL LINES USEFUL FOR THE PRODUCTION OF INTEREST SUBSTANCES |
US6861410B1 (en) | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
MXPA04011249A (en) | 2002-05-14 | 2005-06-06 | Chiron Srl | Mucosal vaccines with chitosan adjuvant and meningococcal antigens. |
US20040228842A1 (en) | 2003-02-27 | 2004-11-18 | Shan Lu | Compositions and methods for cytomegalovirus treatment |
EP1608676A2 (en) | 2003-03-27 | 2005-12-28 | Children's Hospital, Inc. | Nontypeable haemophilus influenzae virulence factors |
EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
EP1766096B1 (en) * | 2004-05-25 | 2013-01-02 | Oregon Health and Science University | Hiv vaccination usingand hcmv-based vaccine vectors |
EP1799255A4 (en) * | 2004-06-25 | 2008-10-01 | Medimmune Vaccines Inc | Recombinant human cytomegalovirus and vaccines comprising heterologous antigens |
JP2009529576A (en) * | 2006-03-10 | 2009-08-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Vaccines against viruses that cause persistent or latent infections |
US20090104227A1 (en) * | 2007-09-21 | 2009-04-23 | Sanofi Pasteur | Vaccine composition for the prevention of cmv infection |
EP2331557B1 (en) | 2008-08-15 | 2013-12-18 | Novartis AG | Alphavirus packaging cell lines |
PL2865387T3 (en) * | 2008-11-21 | 2019-12-31 | Københavns Universitet (University Of Copenhagen) | Priming of an immune response |
EP2451475A2 (en) | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
CA2798214C (en) * | 2010-05-05 | 2021-10-19 | Christian Thirion | Vaccine against beta-herpesvirus infection and use thereof |
US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
PL2691530T3 (en) * | 2011-06-10 | 2019-02-28 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
-
2012
- 2012-10-11 EP EP12816105.6A patent/EP2766385A2/en not_active Withdrawn
- 2012-10-11 WO PCT/IB2012/002491 patent/WO2013054199A2/en active Application Filing
- 2012-10-11 US US14/350,988 patent/US20140348863A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004055166A2 (en) * | 2002-12-13 | 2004-07-01 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
WO2005007689A1 (en) * | 2003-07-11 | 2005-01-27 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
WO2007146024A2 (en) * | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
WO2012006359A1 (en) * | 2010-07-06 | 2012-01-12 | Novartis Ag | Delivery of self-replicating rna using biodegradable polymer particles |
Non-Patent Citations (4)
Title |
---|
ARVIN A M ET AL: "VACCINE DEVELOPMENT TO PREVENT CYTOMEGALOVIRUS DISEASE: REPORT FROM THE NATIONAL VACCINE ADVISORY COMMITTEE", CLINICAL INFECTIOUS DISEASES, THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, US, vol. 39, no. 2, 15 July 2004 (2004-07-15), pages 233 - 239, XP008040187, ISSN: 1058-4838, DOI: 10.1086/421999 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2004 (2004-03-01), SPADERNA S ET AL: "Glycoprotein gpTRL10 of human cytomegalovirus is dispensable for virus replication in human fibroblasts.", XP002694316, Database accession no. PREV200400255310 * |
S. SPADERNA ET AL: "Identification of Glycoprotein gpTRL10 as a Structural Component of Human Cytomegalovirus", JOURNAL OF VIROLOGY, vol. 76, no. 3, 1 February 2002 (2002-02-01), pages 1450 - 1460, XP055057292, ISSN: 0022-538X, DOI: 10.1128/JVI.76.3.1450-1460.2002 * |
SHEN ET AL: "DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates", VACCINE, ELSEVIER LTD, GB, vol. 25, no. 17, 5 April 2007 (2007-04-05), pages 3319 - 3327, XP022022109, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2007.01.011 * |
Also Published As
Publication number | Publication date |
---|---|
US20140348863A1 (en) | 2014-11-27 |
WO2013054199A2 (en) | 2013-04-18 |
EP2766385A2 (en) | 2014-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013054199A3 (en) | Cmv antigens and uses thereof | |
HRP20181343T1 (en) | Methods and compositions for inducing an immune response to egfrviii | |
HK1217942A1 (en) | Lipidated immune response modifier compound compositions, formulations, and methods | |
MX352324B (en) | Multivalent synthetic nanocarrier vaccines. | |
WO2012027365A3 (en) | Targeted multi-epitope dosage forms for induction of an immune response to antigens | |
WO2012149252A3 (en) | Tolerogenic synthetic nanocarriers | |
WO2013177419A3 (en) | Lipid nanoparticle compositions and methods of making and methods of using the same | |
WO2013184976A3 (en) | Compositions and methods for antigen-specific tolerance | |
EP2706991A4 (en) | Multiple antigen presenting immunogenic composition, and methods and uses thereof | |
WO2011109833A3 (en) | Induced dendritic cell compositions and uses thereof | |
WO2013106834A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
WO2011103453A3 (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease | |
WO2012125551A8 (en) | Listeria-based adjuvants | |
EP2825196A4 (en) | Adjuvant and vaccine compositions | |
WO2012109238A3 (en) | Methods for increasing immune responses using agents that directly bind to and activate ire-1 | |
PH12015501101A1 (en) | Method for eliciting an immune response to an immunogen | |
EP3010340A4 (en) | Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency | |
IL238223B (en) | An antigen mhc nanoparticle complex, method of preparation and composition comprising the same | |
MX2014010754A (en) | Compositions comprising secretory - like immunoglobulins. | |
WO2013188627A3 (en) | Cationic lipid vaccine compositions and methods of use | |
WO2013188673A3 (en) | Reassortant btv and ahsv vaccines | |
EP2643014A4 (en) | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response | |
EP3049103A4 (en) | Compositions and methods for reducing antigen-specific immunogenicity | |
WO2012103444A3 (en) | Immunogenic compositions and reagents for preparing | |
WO2014076616A3 (en) | Formulations of 5-azacytidine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12816105 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14350988 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2012816105 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012816105 Country of ref document: EP |